STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
Confidential tips can be sent on Signal at JasonMast.77. RA Capital and a fleet of other investors are putting $175 million behind Oak Hill Bio, a startup trying to revive an experimental Angelman syndrome drug that Roche shelved. Oak Hill is competing with Ultragenyx Pharmaceutical and Ionis Pharmaceuticals, both of which are already running Phase 3 trials of similar drugs for the same disease.
- ▪Confidential tips can be sent on Signal at JasonMast.77.
- ▪RA Capital and a fleet of other investors are putting $175 million behind Oak Hill Bio, a startup trying to revive an experimental Angelman syndrome drug that Roche shelved.
- ▪Oak Hill is competing with Ultragenyx Pharmaceutical and Ionis Pharmaceuticals, both of which are already running Phase 3 trials of similar drugs for the same disease.
STAT News files mainly under health. We currently carry 213 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT |
| Canonical URL | https://www.statnews.com/2026/07/27/ra-captial-oak-hill-bio-spac-ultragenyx-ionis-angelman-syndrome/?utm_campaign=rss |
| Publication time | Mon, 27 Jul 2026 12:00:00 +0000 |
| Retrieval time | 2026-07-27T13:38:34.295Z |
| Last seen | 2026-07-27T13:38:34.295Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | TjNLk9WaKxCI · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
STAT PlusBiotech RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease Merger will help Oak Hill Bio revive old Roche drug for Angelman syndrome Manage alerts for this article Email this article Share this article An image of the chromosomes of someone with Angelman syndrome, a genetic disorder caused by a lack of function of part of chromosome 15Adobe By Jason MastJuly 27, 2026 General Assignment Reporter Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. RA Capital and a fleet of other investors are putting $175 million behind Oak Hill Bio, a startup trying to revive an experimental Angelman syndrome drug that Roche shelved.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
